China Biotechnology Valuation and Liquidity Retreat After July Surge

Overview

This report provides monthly tracking of valuation and liquidity for China's biotechnology sector. It shows that the sector underwent a notable re-rating in mid-July, driven by capital rotation and sector catalysts, before pulling back as overall risk appetite weakened and capital shifted to other healthcare subsectors.

Core views

Both valuation and liquidity followed an intra-month path of rising first and then declining. The mid-month re-rating was primarily driven by fund rebalancing, inflows from other sectors, and positive sector updates; the month-end retreat was related to broader deterioration in risk sentiment and capital rotation toward subsectors such as traditional Chinese medicine, medical devices, and digital healthcare.

Analysis framework

The analysis tracks the China biotechnology sector's 2030E price-to-sales ratio, EV/S, and the sector's turnover as a proportion of Hang Seng Index turnover, comparing changes at end-June, mid-July, and end-July.

Methodology notes

• Valuation AnalysisRelative Valuation

  Price-to-sales ratio and EV/S

  Tracks the biotechnology sector's valuation re-rating and pullback through its 2030E price-to-sales ratio and EV/S.

• Market MicrostructureLiquidity Tracking

  Turnover share

  Measures capital participation and changes in liquidity through the sector's turnover as a proportion of Hang Seng Index turnover.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China biotechnology sector

  Direct coverage of the report

  Strengths

  Benefited from fund rebalancing, cross-sector rotation, and sector catalysts in mid-July, with simultaneous improvements in valuation and liquidity.

  Weaknesses

  Both valuation and trading activity retreated at month-end, with substantial short-term volatility.

  Comparison

  Compared with end-June, the price-to-sales ratio, EV/S, and liquidity remained at higher levels at end-July; compared with the mid-July peak, all had declined.

  Risks

  Further deterioration in overall risk appetite and additional capital rotation toward other subsectors such as traditional Chinese medicine, medical devices, or digital healthcare.

Key data

• 2030E price-to-sales ratioApproximately 3.0x (end-June) → approximately 3.8x (mid-July) → approximately 3.4x (end-July)A significant re-rating occurred in mid-July, followed by a partial reversal at month-end.
• EV/SApproximately 2.4x (end-June) → approximately 3.1x (mid-July) → approximately 2.8x (end-July)The trend was broadly consistent with the price-to-sales ratio.
• Sector liquidity5.8% (end-June) → 9.7% (mid-July) → 6.1% (end-July)Defined as China biotechnology sector turnover as a proportion of Hang Seng Index turnover.

Impact & implications

Mid-month capital inflows demonstrate the sector's high sensitivity to valuation recovery and sector catalysts, while the month-end pullback also indicates that short-term performance remains driven by overall risk appetite and capital rotation across subsectors. Investors should monitor risk sentiment, capital flows, and the sustainability of sector catalysts concurrently.

Risks

• Deterioration in overall market risk appetite could continue to compress sector valuations.
• Capital rotation toward other healthcare subsectors could weaken biotechnology trading activity.
• Insufficient sector catalysts or unmet expectations could undermine the sustainability of the re-rating.
• The report is sector-level tracking and does not constitute investment advice for any individual security.

What to watch

• Whether China biotechnology's 2030E price-to-sales ratio and EV/S can stabilize or resume upward momentum.
• Whether the sector's share of Hang Seng Index turnover rebounds.
• Fund rebalancing and cross-sector capital flows.
• Capital rotation among traditional Chinese medicine, medical devices, digital healthcare, and biotechnology.
• Subsequent sector updates and market events that may affect risk appetite.